Genenta Science SpA ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly28.1MTarget: Sufficient capital to fund operations and strategic acquisitions
Temferon Glioblastoma Multiforme (GBM) 18-Month Survival Rate Annually44.0%Target: Improvement over historical standard of care
Temferon GBM 2-Year Survival Rate Annually29.0%Target: Demonstrate long-term efficacy of cell-based platform
Watch Items
- Strategic Transformation and Rebranding to Saentra Forge S.p.A.Trigger: Shareholder approval at the June 29, 2026 meetingAction: Monitor transition of ticker from GNTA to SAEN and execution of industrial consolidation strategy
- Acquisition of Sòphia High Tech S.r.l.Trigger: Execution of definitive agreements and multi-tranche capital entryAction: Track integration of aerospace and defense manufacturing capabilities
- Partnering of Cell Therapy Platform (Temferon)Trigger: Securing a strategic collaboration or licensing agreementAction: Evaluate non-dilutive funding and clinical development support for solid tumor indications
Research as of 20 Jun 2026